Chad Dugas, MD
Interventional Cardiology · Labadieville, LANPI 1306004841
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,470 of the $33,490 with a category attached, or 64.1%. Cardiovascular Systems Inc. accounts for 72.7% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2021 at $13,957 and has fallen 86.9% since, to $1,831 in 2025.
Across 321 payments — averaging $104.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$24K
- Penumbra, Inc.$2K
- Abiomed$923
- Abbott$803
- Boston Scientific$615
- Novartis$593
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$21,47064%
- Travel & lodging$3,38010%
- Food & beverage$8,63926%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 37 | $24,344 |
| Penumbra, Inc. | 5 | $1,792 |
| Abiomed | 22 | $923 |
| Abbott | 12 | $803 |
| Boston Scientific | 24 | $615 |
| Novartis | 39 | $593 |
| Pfizer | 34 | $562 |
| Shockwave Medical, Inc | 4 | $522 |
| Johnson & Johnson | 30 | $417 |
| Amgen | 22 | $379 |
| Esperion Therapeutics, Inc. | 15 | $274 |
| Angiodynamics, Inc. | 5 | $263 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $240 |
| Boehringer Ingelheim | 6 | $220 |
| Endologix LLC | 1 | $210 |
| Contego Medical, Inc | 3 | $188 |
| Medtronic(2 entities) | 2 | $188 |
| Bard Peripheral Vascular, Inc. | 5 | $175 |
| AstraZeneca | 8 | $124 |
| Kestra Medical Technology Services, Inc. | 5 | $117 |
| Merck | 4 | $68 |
| Philips North America LLC | 4 | $63 |
| Cardiva Medical, Inc. | 3 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $57 |
| Bayer | 2 | $51 |
| Acacia Pharma Inc | 3 | $45 |
| GE HealthCare | 2 | $32 |
| Vital Connect, Inc | 2 | $30 |
| Cvrx, Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Terumo Medical Corporation | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Cook Medical LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Coronary$12,562
- Diamondback Peripheral$12,321
- Peripheral Orbital Atherectomy System$1,903
- Indigo System$1,792
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$476
- Impella$386
- Emboshield NAV6 system$297
- Torus Stent Graft System$210
- ENDOCROSS Device$210
- Protege RX$172
- Coronary Orbital Atherectomy System$156
- JARDIANCE$124
How this compares
$33,490 in reported general payments places this provider in the 80th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 282 | $261,439 |
| EntrestoSacubitril/Valsartan | 88 | $75,481 |
| Repatha SureclickEvolocumab | 93 | $63,432 |
| XareltoRivaroxaban | 64 | $44,475 |
| JardianceEmpagliflozin | 38 | $35,183 |
| NexletolBempedoic Acid | 39 | $19,973 |
| WegovySemaglutide | 14 | $18,864 |
| BrilintaTicagrelor | 13 | $12,340 |
| FarxigaDapagliflozin Propanediol | 18 | $9,951 |
| Praluent PenAlirocumab | 13 | $9,650 |
| VascepaIcosapent Ethyl | 24 | $9,455 |
| NexlizetBempedoic Acid/Ezetimibe | 20 | $7,700 |
| Ranolazine ErRanolazine | 84 | $6,596 |
| Pitavastatin Calcium | 43 | $6,082 |
| Ezetimibe | 270 | $5,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $562 | $261,439282 claims |
| NovartisEntresto | $593 | $75,48188 claims |
| Johnson & JohnsonXarelto | $417 | $44,47564 claims |
| Boehringer IngelheimJardiance | $220 | $35,18338 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $274 | $27,67359 claims |
| AstraZenecaBrilinta, Farxiga | $124 | $22,29131 claims |
| Novo NordiskWegovy | $16 | $18,86414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Labadieville
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
- Pradeep NairHouma$212K
- Jorge CastellanosBaton Rouge$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.